Inclusion Criteria:

- Histologically or cytologically documented non-small cell carcinoma of the lung
diagnosed within 16 weeks prior to study enrollment.

- Patient must be at least 18 years old at the time of consent.

- Stage III A or III B disease.

- Patients must be able to start study treatment within 6 weeks of study enrollment.

- Induction chemotherapy is allowed.

- Marginally resectable or unresectable at presentation.

- If the patient had exploratory thoracotomy, it must be done at least 3 weeks prior to
enrollment.

Exclusion Criteria:

- Evidence of distant metastasis.

- Prior thoracic radiotherapy.

- Any history of allergic reaction to taxanes.

- Prior tumor resection. Candidate for upfront curative surgery.

- Pleural effusion visible on chest x-ray or the scout view of the CT chest.

- Unintentional weight loss within the month prior to diagnosis ≥ 10%.

- Previous or concomitant malignancy other than early stage tumor treated more than 3
years ago for cure.

- The presence of PET positive contralateral hilar disease.